5 days ago · Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February 2011. For information on our organization please visit the Janssen Infectious …

Janssen Vaccines, formerly Crucell, is a biotechnology company specializing in vaccines and biopharmaceutical technologies. It was formed when Johnson & Johnson acquired the Dutch …

Crucell, a biopharmaceutical company specializing in vaccines and antibodies to fight infectious disease worldwide, was acquired by Johnson & Johnson. The purchase equipped Johnson & …

Crucell N.V. is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious …

Mar 8, 2011 · Johnson & Johnson (J&J) has acquired Netherlands-based biopharmaceutical company Crucell for close to $2.4 billion dollars, moving J&J prominently into the arena of …

Crucell is a global biopharmaceutical company dedicated to bringing meaningful innovation to global health.

Jul 8, 2011 · Crucell is one of the major suppliers of vaccines to UNICEF and the developing world. Crucell was the first manufacturer to launch a fully-liquid pentavalent vaccine. Called …

Jan 5, 2015 · Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and …

Aug 10, 2012 · Crucell is a biopharmaceutical company dedicated to bringing meaningful innovation to global health. Our teams focus on the discovery, development, manufacture and …

Summarized under the catch-phrase “huMADE,” Crucell focuses on the development of human antibody-based therapeutics for treatment of cancer and inflammatory diseases and for the …